References
-
1
Ahrens B, Muller-Oerlinghausen B.
Does lithium exert and independent antisucidal effect?.
Pharmacopsychiatry.
2001;
34
132-136
-
2 Baldessarini RJ, Tarazi FI. Pharmacotherapy of psychiatric disorders. Chapters 17 and 18 in: Brunton LL, Lazo JS, Parker KL, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 11th edition. McGraw-Hill Press, New York 2005: 429-500
-
3
Baldessarini RJ, Tondo L.
Lithium and suicidal risk.
Bipolar Disord.
2008;
10
114-115
-
4
Baldessarini RJ, Tondo L, Davis P. et al .
Decreased risk of suicides and attempts during long-term lithium treatment: meta-analytic review.
Bipolar Disord.
2006;
8
625-639
-
5
Baldessarini RJ, Tondo L, Hennen J.
Antisuicidal effects of lithium in manic-depressive disorders.
J Clin Psychiatry.
1999;
60
((Suppl. 2))
77-84
-
6
Bowden CL, Calabrese JR, Sachs G. et al .
Placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder.
Arch Gen Psychiatry.
2003;
60
392-400
-
7
Calabrese JR, Bowden CL, Sachs G. et al .
Placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder.
J Clin Psychiatry.
2003;
64
1013-1024
-
8
Collins JC, MacFarland BH.
Divalproex, lithium and suicide among Medicaid patients with bipolar disorder.
J Affect Disord.
2008;
107
23-28
-
9
Goodwin FK, Fireman B, Simon GE. et al .
Suicide risk in bipolar disorder during treatment with lithium and divalproex.
JAMA.
2003;
290
1467-1473
-
10
Greil W, Ludwig-Mayerhofer W, Erazo N. et al .
Lithium vs. carbamazepine in the maintenance treatment of bipolar disorders: randomized study.
J Affect Disord.
1997;
43
151-161
-
11
Kallner G Lindelius E, Petterson U, Stockman O. et al .
Mortality in 497 patients with affective disorders attending a lithium clinic or after having left.
Pharmacopsychiatry.
2000;
33
8-13
-
12
Kessing LV, Søndergård L, Kvist K. et al .
Suicide risk in patients treated with lithium.
Arch Gen Psychiatry.
2005;
62
860-866
-
13
Meltzer HY, Alphs L, Green AI. et al .
Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).
Arch Gen Psychiatry.
2003;
60
82-91
-
14
Müller-Oerlinghausen B.
Pharmacological suicide prevention under special consideration of lithium salts.
Psychiatr Prax.
2007;
34
((Suppl. 3))
S292-S295
-
15
Simhandl C, Mersch J.
Lithium and bipolar disorder – a renaissance?.
Neuropsychiatrie.
2007;
21
121-130
-
16
Tondo L, Baldessarini RJ.
Risks of suicidal ideation, attempts and suicides among 2 826 men and women with types I and II bipolar, and recurrent major depressive disorders.
Acta Psychiatr Scand.
2007;
116
419-428
-
17
Tondo L, Baldessarini RJ, Hennen J. et al .
Lithium treatment and risk of suicidal behavior in bipolar disorder patients.
J Clin Psychiatry.
1998;
59
405-414
-
18
Tondo L, Isacsson G, Baldessarini RJ.
Suicide in bipolar disorder: Risk and prevention.
CNS Drugs.
2003;
17
491-511
-
19
US Food and Drug Administration (FDA) .
Antiepileptic drugs statistical review and evaluation: Antiepileptic Drugs AEDs) and Suicidality.
, Accessed at:
http://http.www.fda.gov/ohrms/dockets/ac/08/ briefing/2008-4372b1-01-fda.pdf
, on 20 August,
2008;
-
20
Yerevanian BI, Koeka RJ, Mintz J.
Lithium, ACs and suicidal behavior in bipolar disorder.
J Affect Disord.
2003;
73
223-228
-
21
Yerevanian BI, Koek RJ, Mintz J.
Bipolar pharmacotherapy and suicidal behavior: lithium, divalproex, and carbamazepine.
J Affect Disord.
2007;
103
5-11
Correspondence
Dr. R. J. Baldessarini
Mailman Research Center 312
McLean Hospital
115 Mill Street
Belmont
MA 02178-9106
USA
Phone: +1/617/855 32 03
Fax: +1/617/855 34 79
Email: rjb@mclean.org
